In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia. Orna Therapeutics (through its wholly owned ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.

Moreover, in June 2024, Vertex announced its partnership with Moderna Therapeutics, which aims to advance mRNA-based treatments of cystic fibrosis, thus reiterating the company's awareness of ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR ...

Sionna Therapeutics is working on therapies for ... Sionna is working on a medicines it claims can challenge Vertex Pharmaceuticals’ dominant cystic fibrosis business. The company designed ...

(Image Credits: Pixabay) Immuneel Therapeutics on Monday launched Qartemi, a CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). According to the company’s statement, it is ...